Mangalam Drugs Faces ₹15.57 Crore Bank Loan Default Overdue Past 30 Days

Market snapshot: Mangalam Drugs and Organics Limited has disclosed ongoing defaults on its revolving working capital facilities with Bank of Maharashtra and Bank of Baroda. The total overdue debt is ₹15.57 crore as of the latest regulatory filing, with both lending accounts remaining in default for over 30 days due to lingering cash flow constraints.

Data Snapshot

• The overdue balance with Bank of Maharashtra cash credit account stands at ₹9.51 crore as of the July 15, 2026 reporting period, with the default beginning on October 17, 2025.
• The overdue balance with Bank of Baroda cash credit account stands at ₹6.06 crore as of the July 15, 2026 reporting period, with the default beginning on October 20, 2025.
• Mangalam Drugs posted a standalone net loss of ₹7.55 crore for the quarter ended June 30, 2026, which is a significant improvement over the standalone net loss of ₹13.73 crore in the corresponding prior-year quarter.

What's Changed

• The total overdue default amount decreased marginally to ₹15.57 crore from the ₹15.58 crore reported as of June 15, 2026, driven by a minor repayment on the Bank of Maharashtra facility (derived: ₹9.51 crore vs ₹9.52 crore).
• The standalone net loss narrowed by approximately 45% YoY to ₹7.55 crore in Q1 FY27 from ₹13.73 crore in Q1 FY26, highlighting improved operating efficiencies.

Key Takeaways

• Revolving working capital balances have remained continuously in excess of the sanctioned drawing power for over 30 days, triggering the default.
• The default duration has stretched to nearly 11 months, indicating persistent balance sheet pressure and tight liquidity.
• Operating revenue has remained flat at ₹57.12 crore for the quarter ended June 30, 2026, compared to ₹57.21 crore in the corresponding quarter of 2025.

SAHI Perspective

While Mangalam Drugs has demonstrated progress in narrowing its operating and net losses through tighter cost controls and improved inventory management, the prolonged working capital default remains a severe systemic risk. Spanning nearly 11 months, these cash credit defaults highlight a critical gap in liquid capital. Without a formal restructuring package or equity infusion, the threat of lenders initiating recovery actions or classifying the loans as NPAs remains exceptionally high.

Market Implications

The prolonged default is expected to keep the company's credit rating under severe pressure and restrict its ability to secure fresh credit facilities. This working capital bottleneck could eventually impact raw material procurement, potentially restricting production volumes at the company's Vapi API manufacturing facility.

Trading Signals

Market Bias: Bearish

The outlook remains highly cautious due to persistent bank defaults of ₹15.57 crore that have run for nearly 11 months, combined with a quarterly net loss of ₹7.55 crore.

Underweight: Pharmaceuticals

Trigger Factors:

• Announcement of any debt settlement, restructuring agreement, or capital infusion.
• Action taken by Bank of Baroda or Bank of Maharashtra under debt recovery laws.
• Cash flow improvement in the upcoming quarterly financial results.

Time Horizon: Near-term (0-3 months)

Industry Context

The active pharmaceutical ingredients (API) and bulk drugs manufacturing sector is highly capital-intensive, requiring substantial working capital to maintain inventory cycles. Debt-heavy companies face amplified stress under competitive pricing environments, where cash constraints quickly disrupt manufacturing schedules.

Key Risks to Watch

• Potential classification of the cash credit accounts as Non-Performing Assets (NPAs) by the banks.
• Lenders initiating legal action under recovery of debt laws.
• Supply chain disruptions if credit limits with key raw material suppliers are curtailed.

Recent Developments

On August 12, 2026, Mangalam Drugs reported its Q1 FY27 results, showing a standalone net loss of ₹7.55 crore, down from a loss of ₹13.73 crore in Q1 FY26, on stable revenue of ₹57.12 crore. Additionally, the company scheduled its 53rd Annual General Meeting (AGM) for September 23, 2026, where it will seek approval for the appointment of new statutory and secretarial auditors following the resignation of Ragini Chokshi & Co.

Closing Insight

While narrowing operational losses indicate that Mangalam Drugs is attempting a turnaround, the looming ₹15.57 crore bank default is a roadblock that must be cleared to stabilize the company's operational viability and ensure long-term solvency.

High Performance Trading with SAHI.